Significant response to pembrolizumab plus lenvatinib in Epstein–Barr-virus-associated intrahepatic cholangiocarcinoma: a case report

Significant response to pembrolizumab plus lenvatinib in Epstein–Barr-virus-associated intrahepatic cholangiocarcinoma: a case report

ABSTRACTBackground The prognosis for advanced intrahepatic cholangiocarcinoma (iCCA) is poor, and there remains an urgent need to develop efficient systemic therapy. The efficacy of Pembrolizumab immunotherapy combined with lenvatinibin in iCCA is still unclear. The role of Epstein–Barr-virus (EBV)...

Full description

Bibliographic Details
Main Authors: Lisha Li, Dandan Yu, Jinru Yang, Fangyuan Zhang, Dejun Zhang, Zhenyu Lin, Menglan Zhai, Jing Wang, Tao Zhang, Lei Zhao
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Cancer Biology & Therapy
Subjects:
Pembrolizumab
lenvatinib
Epstein–Barr virus
intrahepatic cholangiocarcinoma
Online Access:https://www.tandfonline.com/doi/10.1080/15384047.2024.2338644

Similar Items

Similar Items